MiR-1207 overexpression promotes cancer stem cell-like traits in ovarian cancer by activating the Wnt/β-catenin signaling pathway

Oncotarget

Volumn 6, Issue 30, 2015, Pages 28882-28894

  Wu, Geyan ^a,b,c   Liu, Aibin ^a   Zhu, Jinrong ^a   Lei, Fangyong ^b   Wu, Shu ^b   Zhang, Xin ^b   Ye, Liping ^b   Cao, Lixue ^a   He, Shanyang ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^c SUN YAT SEN UNIVERSITY   (China)

Author keywords

Cancer stem cells; Ovarian cancer; Tumorigenicity; Wnt catenin signaling

Indexed keywords

AXIN; BETA CATENIN; CD133 ANTIGEN; MICRORNA; MICRORNA 1207; PEPTIDES AND PROTEINS; PROTEIN AXIN2; PROTEIN ICAT; SECRETED FRIZZLED RELATED PROTEIN 1; UNCLASSIFIED DRUG; WNT PROTEIN; ANTISENSE OLIGONUCLEOTIDE; AXIN2 PROTEIN, HUMAN; CTNNB1 PROTEIN, HUMAN; CTNNBIP1 PROTEIN, HUMAN; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; MEMBRANE PROTEIN; MIRN1207 MICRORNA, HUMAN; PEPTIDE; PROM1 PROTEIN, HUMAN; PROM1 PROTEIN, MOUSE; SFRP1 PROTEIN, HUMAN; SIGNAL PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER STEM CELL; CARCINOGENICITY; CONTROLLED STUDY; CORRELATIONAL STUDY; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; UPREGULATION; WNT SIGNALING PATHWAY; ANIMAL; BAGG ALBINO MOUSE; CELL PROLIFERATION; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; METABOLISM; MORTALITY; NUDE MOUSE; OVARIAN NEOPLASMS; PATHOLOGY; PHENOTYPE; TIME FACTOR; TUMOR CELL LINE; TUMOR VOLUME;

AC133 ANTIGEN; ANIMALS; ANTIGENS, CD; AXIN PROTEIN; BETA CATENIN; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOPROTEINS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MEMBRANE PROTEINS; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; NEOPLASTIC STEM CELLS; OLIGONUCLEOTIDES, ANTISENSE; OVARIAN NEOPLASMS; PEPTIDES; PHENOTYPE; TIME FACTORS; TRANSFECTION; TUMOR BURDEN; UP-REGULATION; WNT SIGNALING PATHWAY;

EID: 84945161700     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4921     Document Type: Article

References (41)

1. Vargas AN. Natural history of ovarian cancer. Ecancermedicalscience. 2014; 8:465.
2. Hannibal CG, Cortes R, Engholm G, Kjaer SK. Survival of ovarian cancer patients in Denmark: excess mortality risk analysis of five-year relative survival in the period 1978-2002. Acta obstetricia et gynecologica Scandinavica. 2008; 87:1353-1360.
3. Tomao F, Papa A, Rossi L, Strudel M, Vici P, Lo Russo G, Tomao S. Emerging role of cancer stem cells in the biology and treatment of ovarian cancer: basic knowledge and therapeutic possibilities for an innovative approach. Journal of experimental & clinical cancer research: CR. 2013; 32:48.
4. Chekerov R, Braicu I, Castillo-Tong DC, Richter R, Cadron I, Mahner S, Woelber L, Marth C, Van Gorp T, Speiser P, Zeillinger R, Vergote I, Sehouli J. Outcome and clinical management of 275 patients with advanced ovarian cancer International Federation of Obstetrics and Gynecology II to IV inside the European Ovarian Cancer Translational Research Consortium-OVCAD. International journal of gynecological cancer: official journal of the International Gynecological Cancer Society. 2013; 23:268-275.
5. Peiretti M, Bristow RE, Zapardiel I, Gerardi M, Zanagnolo V, Biffi R, Landoni F, Bocciolone L, Aletti GD, Maggioni A. Rectosigmoid resection at the time of primary cytoreduction for advanced ovarian cancer. A multi-center analysis of surgical and oncological outcomes. Gynecologic oncology. 2012; 126:220-223.
6. Chen CY, Chang HP, Ng KK, Wang CC, Lai CH, Chao A. Long-term disease-free survival in three ovarian cancer patients with a single relapse. European journal of gynaecological oncology. 2012; 33:321-323.
7. Vermeulen L, Sprick MR, Kemper K, Stassi G, Medema JP. Cancer stem cells-old concepts, new insights. Cell death and differentiation. 2008; 15:947-958.
8. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, Visvader J, Weissman IL, Wahl GM. Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer research. 2006; 66:9339-9344.
9. Pattabiraman DR, Weinberg RA. Tackling the cancer stem cells-what challenges do they pose? Nature reviews Drug discovery. 2014; 13:497-512.
10. Nusse R, Fuerer C, Ching W, Harnish K, Logan C, Zeng A, ten Berge D, Kalani Y. Wnt signaling and stem cell control. Cold Spring Harbor symposia on quantitative biology. 2008; 73:59-66.
11. Valenta T, Hausmann G, Basler K. The many faces and functions of beta-catenin. The EMBO journal. 2012; 31:2714-2736.
12. Liu J, Pan S, Hsieh MH, Ng N, Sun F, Wang T, Kasibhatla S, Schuller AG, Li AG, Cheng D, Li J, Tompkins C, Pferdekamper A, Steffy A, Cheng J, Kowal C, et al. Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974. Proceedings of the National Academy of Sciences of the United States of America. 2013; 110:20224-20229.
13. Arend RC, Londono-Joshi AI, Straughn JM Jr, Buchsbaum DJ. The Wnt/beta-catenin pathway in ovarian cancer: a review. Gynecologic oncology. 2013; 131:772-779.
14. Steg AD, Bevis KS, Katre AA, Ziebarth A, Dobbin ZC, Alvarez RD, Zhang K, Conner M, Landen CN. Stem cell pathways contribute to clinical chemoresistance in ovarian cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2012; 18:869-881.
15. Chau WK, Ip CK, Mak AS, Lai HC, Wong AS. c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/betacatenin-ATP-binding cassette G2 signaling. Oncogene. 2013; 32:2767-2781.
16. Rao TP, Kuhl M. An updated overview on Wnt signaling pathways: a prelude for more. Circulation research. 2010; 106:1798-1806.
17. MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Developmental cell. 2009; 17:9-26.
18. Ramachandran I, Ganapathy V, Gillies E, Fonseca I, Sureban SM, Houchen CW, Reis A, Queimado L. Wnt inhibitory factor 1 suppresses cancer stemness and induces cellular senescence. Cell death & disease. 2014; 5:e1246.
19. Komiya Y, Habas R. Wnt signal transduction pathways. Organogenesis. 2008; 4:68-75.
20. Voronkov A, Krauss S. Wnt/beta-catenin signaling and small molecule inhibitors. Current pharmaceutical design. 2013; 19:634-664.
21. Malinauskas T, Jones EY. Extracellular modulators of Wnt signalling. Current opinion in structural biology. 2014; 29C:77-84.
22. Kimelman D, Xu W. beta-catenin destruction complex: insights and questions from a structural perspective. Oncogene. 2006; 25:7482-7491.
23. Daniels DL, Weis WI. ICAT inhibits beta-catenin binding to Tcf/Lef-family transcription factors and the general coactivator p300 using independent structural modules. Molecular cell. 2002; 10:573-584.
24. Lieberman J, Slack F, Pandolfi PP, Chinnaiyan A, Agami R, Mendell JT. Noncoding RNAs and cancer. Cell. 2013; 153:9-10.
25. Takubo K, Ohmura M, Azuma M, Nagamatsu G, Yamada W, Arai F, Hirao A, Suda T. Stem cell defects in ATM-deficient undifferentiated spermatogonia through DNA damage-induced cell-cycle arrest. Cell stem cell. 2008; 2:170-182.
26. Curley MD, Therrien VA, Cummings CL, Sergent PA, Koulouris CR, Friel AM, Roberts DJ, Seiden MV, Scadden DT, Rueda BR, Foster R. CD133 expression defines a tumor initiating cell population in primary human ovarian cancer. Stem cells. 2009; 27:2875-2883.
27. Marson A, Foreman R, Chevalier B, Bilodeau S, Kahn M, Young RA, Jaenisch R. Wnt signaling promotes reprogramming of somatic cells to pluripotency. Cell stem cell. 2008; 3:132-135.
28. Bruttel VS, Wischhusen J. Cancer stem cell immunology: key to understanding tumorigenesis and tumor immune escape? Frontiers in immunology. 2014; 5:360.
29. Marsden CG, Wright MJ, Pochampally R, Rowan BG. Breast tumor-initiating cells isolated from patient core biopsies for study of hormone action. Methods in molecular biology. 2009; 590:363-375.
30. Zhang QH, Dou HT, Xu P, Zhuang SC, Liu PS. Tumor Recurrence and Drug Resistance Properties of Side Population Cells in High Grade Ovary Cancer. Drug Res (Stuttg). 2015; 65:153-157.
31. Wang Y, Krivtsov AV, Sinha AU, North TE, Goessling W, Feng Z, Zon LI, Armstrong SA. The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML. Science. 2010; 327:1650-1653.
32. Malanchi I, Peinado H, Kassen D, Hussenet T, Metzger D, Chambon P, Huber M, Hohl D, Cano A, Birchmeier W, Huelsken J. Cutaneous cancer stem cell maintenance is dependent on beta-catenin signalling. Nature. 2008; 452:650-653.
33. Hsu TH, Jiang SY, Chan WL, Eckert RL, Scharadin TM, Chang TC. Involvement of RARRES3 in the regulation of Wnt proteins acylation and signaling activities in human breast cancer cells. Cell Death Differ. 2015; 22:801-814.
34. Schlange T, Matsuda Y, Lienhard S, Huber A, Hynes NE. Autocrine WNT signaling contributes to breast cancer cell proliferation via the canonical WNT pathway and EGFR transactivation. Breast cancer research: BCR. 2007; 9:R63.
35. Joesting MS, Perrin S, Elenbaas B, Fawell SE, Rubin JS, Franco OE, Hayward SW, Cunha GR, Marker PC. Identification of SFRP1 as a candidate mediator of stromalto-epithelial signaling in prostate cancer. Cancer research. 2005; 65:10423-10430.
36. Pinarbasi E, Gunes EG, Pinarbasi H, Donmez G, Silig Y. AXIN2 polymorphism and its association with prostate cancer in a Turkish population. Medical oncology. 2011; 28:1373-1378.
37. Huth L, Rose M, Kloubert V, Winkens W, Schlensog M, Hartmann A, Knuchel R, Dahl E. BDNF is associated with SFRP1 expression in luminal and basal-like breast cancer cell lines and primary breast cancer tissues: a novel role in tumor suppression? PloS one. 2014; 9:e102558.
38. Li AF, Hsu PK, Tzao C, Wang YC, Hung IC, Huang MH, Hsu HS. Reduced axin protein expression is associated with a poor prognosis in patients with squamous cell carcinoma of esophagus. Annals of surgical oncology. 2009; 16:2486-2493.
39. Domingues MJ, Rambow F, Job B, Papon L, Liu W, Larue L, Bonaventure J. beta-catenin inhibitor ICAT modulates the invasive motility of melanoma cells. Cancer research. 2014; 74:1983-1995.
40. Yang F, Zhang L, Wang F, Wang Y, Huo XS, Yin YX, Wang YQ, Zhang L, Sun SH. Modulation of the unfolded protein response is the core of microRNA-122-involved sensitivity to chemotherapy in hepatocellular carcinoma. Neoplasia. 2011; 13:590-600.
41. Hahn WC, Dessain SK, Brooks MW, King JE, Elenbaas B, Sabatini DM, DeCaprio JA, Weinberg RA. Enumeration of the simian virus 40 early region elements necessary for human cell transformation. Molecular and cellular biology. 2002; 22:2111-2123.